Ken Lin, MD
Ophthalmology · Honolulu, HINPI 1124169636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$577
- Amgen$453
- Sun Pharmaceutical Industries Inc.$432
- Alcon$318
- Bausch & Lomb, A Division Of Bausch Health US, LLC$317
- Eyevance Pharmaceuticals LLC$233
- plus $2K from 15 others
What the payments were for
- Food & beverage$3,90698%
- Education$802%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $577 |
| Amgen(2 entities) | 12 | $453 |
| Sun Pharmaceutical Industries Inc. | 17 | $432 |
| Alcon | 9 | $318 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $317 |
| Eyevance Pharmaceuticals LLC | 5 | $233 |
| Dompe US, Inc. | 4 | $199 |
| Novartis | 9 | $197 |
| Oyster Point Pharma, Inc. | 9 | $175 |
| Bausch & Lomb Americas Inc. | 8 | $172 |
| Tarsus Pharmaceuticals, Inc. | 7 | $169 |
| Aerie Pharmaceuticals, Inc. | 8 | $155 |
| Mallinckrodt Hospital Products Inc. | 5 | $148 |
| Kala Pharmaceuticals, Inc. | 6 | $134 |
| Johnson & Johnson Vision Care, Inc. | 5 | $112 |
| Shire North American Group Inc | 3 | $61 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $48 |
| Sight Sciences, Inc. | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $28 |
| Harrow Eye, LLC | 1 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,005 in reported general payments places this provider in the 60th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 689 | $765,756 |
| OxervateCenegermin-Bkbj | 12 | $338,855 |
| Alphagan PBrimonidine Tartrate | 304 | $170,531 |
| XiidraLifitegrast | 114 | $116,361 |
| XdemvyLotilaner | 48 | $95,312 |
| Brimonidine Tartrate | 225 | $34,767 |
| MieboPerfluorohexyloctane/Pf | 42 | $34,707 |
| VyzultaLatanoprostene Bunod | 54 | $21,251 |
| LumiganBimatoprost | 29 | $20,510 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $19,214 |
| TyrvayaVarenicline Tartrate | 28 | $18,038 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $15,664 |
| ProlensaBromfenac Sodium | 26 | $11,161 |
| RhopressaNetarsudil Mesylate | 22 | $9,414 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $7,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $577 | $976,0111,057 claims |
| Dompe US, Inc.Oxervate | $199 | $338,85512 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $172 | $172,320210 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $169 | $95,31248 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $155 | $25,07757 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $175 | $18,03828 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Bepreve | $317 | $17,21937 claims |
| AlconSimbrinza | $318 | $7,04230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.